{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05599984","nct_id":"NCT05599984","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05599984. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive escalating doses of ABBV-706 until doses for optimization are determined, as part of an approximately 2 year treatment period.","label":"Part 1: ABBV-706 Monotherapy Dose Escalation","type":"EXPERIMENTAL"},{"description":"Participants with small cell lung cancer will receive varying doses of ABBV-706 in a randomized manner until the recommended phase 2 dose (RP2D) is achieved, as part of an approximately 2 year treatment period..","label":"Part 2: ABBV-706 Monotherapy Dose Optimization and Expansion","type":"EXPERIMENTAL"},{"description":"Participants will receive ABBV-706 in combination with budigalimab, as part of an approximately 2 year treatment period.","label":"Part 3a: ABBV-706 + Budigalimab","type":"EXPERIMENTAL"},{"description":"Participants will receive ABBV-706 in combination with carboplatin or cisplatin, as part of an approximately 2 year treatment period.","label":"Part 3b: ABBV-706 + Platinum Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants with relapsed/refractory (R/R) central nervous system (CNS) tumors will receive ABBV-706 as a monotherapy at or below the maximum tolerated dose (MTD) maximum administered dose (MAD), as part of an approximately 2 year treatment period.","label":"Part 4a: ABBV-706 Monotherapy Dose Expansion CNS Tumors","type":"EXPERIMENTAL"},{"description":"Participants with R/R neuroendocrine carcinomas (NECs) will receive IV Infused ABBV-706 as a monotherapy at or below the MTD/MAD, as part of an approximately 2 year treatment period.","label":"Part 4b: ABBV-706 Monotherapy Dose Expansion NECs","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":288,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ABBV-706","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Budigalimab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"}],"last_update":"2026-05-07","lead_sponsor":"AbbVie","official_title":"A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants With Adverse Events (AE)","timeFrame":"Up to Approximately 2 Years"},{"measure":"Maximum Observed Serum/Plasma Concentration (Cmax) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"measure":"Time to Cmax (Tmax) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"measure":"Terminal Phase Elimination Half-Life (t1/2) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"measure":"Area Under the Serum/Plasma Concentration-Time Curve (AUC) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"measure":"Antidrug Antibodies (ADAs)","timeFrame":"Up to Approximately 2 Years"},{"measure":"Neutralizing Antibodies (nAbs)","timeFrame":"Up to Approximately 2 Years"},{"measure":"Percentage of Participants with Objective Response, for Participants with Extracranial Solid Tumors","timeFrame":"Up to Approximately 2 Years"},{"measure":"Recommended Phase 2 Dose (RP2D) of ABBV-706","timeFrame":"Up to Approximately 2 Years"},{"measure":"Percentage of Participants with Objective Response for Participants with Central Nervous System (CNS) Tumors","timeFrame":"Up to Approximately 2 Years"},{"measure":"Duration of response (DOR) for Participants with Confirmed CR/PR","timeFrame":"Up to Approximately 2 Years"},{"measure":"Percentage of Participants with Clinical Benefit","timeFrame":"Up to Approximately 2 Years"},{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to Approximately 2 Years"},{"measure":"Overall survival (OS)","timeFrame":"Up to Approximately 2 Years"}],"references":[{"citation":"Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M, Dowlati A, Morgensztern D, Papadopoulos KP, Choudhury NJ, Vieito M, Bar J, Kim JH, Akerley W, Kim TM, Kim YC, Paz-Ares L, Ahn MJ, Yokouchi H, Meiman D, Munasinghe W, Ogunyankin O, Jahchan N, Wang S, Ferlini C, Robinson RR, Kohlhapp FJ, Palenski T, Rivell G, Hingorani P, Chandana S. SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. 2026 Aug;32(8):2898-2908. doi: 10.1038/s41591-026-04452-0. Epub 2026 Jun 1.","pmid":"42225988","type":"DERIVED"}],"start_date":{"date":"2022-12-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05599984"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05599984"}